Panel Discussion: Comparing Small Molecules, Peptides & Antibodies to Identify the Optimal Modality for Clinical, Commercial & Patient Success
3:15 pm - Wednesday 3rd March 2027
- Which modality delivers the greatest advantage across efficacy, safety, tissue penetration and durability, and does the answer depend on the target?
- How much should patient-centric considerations such as dosing frequency, convenience and route of administration influence development decisions?
- When evaluating a new GPCR program, how much does modality choice influence commercial differentiation, partnering opportunities and long-term value creation?
